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€17.570/LYG. CONCLUSIONS: It was possible to develop a unique base case
Markov model for early breast cancer from the literature and to adjust this
model taking various published assumptions into account. The adaptation of
various assumptions resulted in differences in outcomes of CEAs of adjuvant
breast cancer therapies. This case example demonstrates the importance of the
development of standardized model structures for adjuvant breast cancer ther-
apies.
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OBJECTIVES: Breast cancer is the most common malignant disease in Western
women. In the ONCOTYROL research center, a Breast Cancer Outcomes & Policy
(ONCOTYROL) model was developed to evaluate the cost-effectiveness of the
new 21-gene assay that supports personalized decisions on adjuvant chemo-
therapy. The goal of this study was to validate our Oncotyrol-model. METHODS:
The 21-gene assay was evaluated by simulating a hypothetical cohort of 50-year
old women over a lifetime time horizon using a discrete event simulation. Main
model outcomes were life-years gained, quality-adjusted life-years (QALYs) and
costs. Based on the new ISPOR-SMDM best practice recommendations, the
model has been validated. Major focus was on our experiences of the cross
validation, i.e. the comparison of modeling results between the discrete-event-
simulation ONCOTYROL-model and the THETA-model (Toronto Health Eco-
nomics and Technology Assessment Collaborative) which is a Markov model.
Therefore, the Oncotyrol-model has been populated with the Canadian THETA-
model parameters. Cross validation started with a comparison of the natural
history followed by QALYs and costs. RESULTS: The relative differences varied
among the model outcomes. The smallest differences we found for costs, the high-
est for QALYs. All differences were smaller than 2.5%. The comparison of the effi-
ciency frontiers showed that small differences due to the modeling approach can
lead to a different set of non-dominated test-treatment strategies. The cross model
validation involved several challenges: distinguishing between outcomes differ-
ences due to different modeling techniques and errors, definitions for meaningful
differences and comparison techniques (mean estimates, distributions, multivar-
iate outcomes). CONCLUSIONS: Cross-model validation was crucial to identify and
correct modeling errors and to explain remaining differences of modeling results.
However, small differences can lead to relevant changes in cost-effectiveness re-
sults.
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OBJECTIVES: Compliance and treatment duration can have a significant impact
on costs and health outcomes in health-economic assessments, especially in
high-cost therapy areas such as oncology. The objective of this study was to
systematically review different methods for addressing treatment compliance
and discontinuation in oncology economic models, critique the identified meth-
odologies, and highlight best practices. METHODS: A systematic review was un-
dertaken to investigate the different methods that could be used to include com-
pliance and treatment discontinuation in economic modelling in oncology
populations. MEDLINE, Embase, EconLit and the Cochrane Library (from 2000 on-
wards), and technology assessment documents and manufacturer submissions to
the National Institute for Health and Clinical Excellence (NICE) were searched for
economic analyses which mentioned compliance or discontinuation. Results were
filtered using pre-specified selection criteria and data extracted into a pre-defined
template. RESULTS: Sixty-eight publications of 51 models were included, compris-
ing 20 journal publications and 48 technology appraisal documents. Possible meth-
ods were divided into ten categories. Seven studies mentioned discontinuations,
but did not include a modelling approach. There was a lack of consensus regarding
the methods applied. Twenty studies varied dose or discontinuation rate in sensi-
tivity analyses, although impact on overall outcomes was rarely explored. Dose
intensity was most often adopted from clinical trials. Effects on the overall out-
comes by inclusion of discontinuations or dose intensity adjustments were rarely
discussed. Overall, the authors of included publications poorly justified their meth-
ods regarding compliance assumptions. CONCLUSIONS: The combination of sev-
eral methods could improve accuracy of modelling discontinuations. Discontinu-
ations should affect three aspects of the model: transition probabilities, costs and
effects. Clear explanations and justification of the included parameter assump-
tions should also be improved in NICE submissions to enhance likelihood of posi-
tive recommendation. Standardised guidelines could raise more attention to com-
pliance in economic modelling and could improve the accuracy of economic
models.
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PATIENT HEALTH CARE ACCESS
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OBJECTIVES: The UK NHS is currently undergoing the most significant reforms to
its structure possibly since the NHS was formed. There are many questions at all
levels regarding the reforms, and this research aimed to address some of them The
objectives were – 1) To assess how the reforms were proceeding and what issues
they had been encountered, and 2) To determine how the delivery of care has been
impacted at a grassroots level.METHODS:We adopted a two phased approach. The
first phase involved extensive literature review in order to assess how the reforms
were expected to proceed, what the outcomes were likely/expected to be and when
key milestones were expected to be met. The second phase was centred on primary
research carried out by Double Helix personnel. Key stakeholders in the reforming
NHS at all levels were approached and data was collected using a combination of
qualitative and quantitative methodologies. RESULTS:While the vision of the NHS
reforms was very clear from the outset, the actual progression on the ground has
been met with considerable challenges. Even while CCGs in the first wave were in
the process of undergoing assessment, changes to the overall architecture of the
reforms were continuous. Key personnel at all levels lacked a clear grasp of what
the following 12 months would bring, and various influencer and guideline bodies
faced uncertain futures or lacked a clear remit. At the stage of writing there was no
clear evidence either way to suggest that the reforms were having an impact on
frontline health care delivery. CONCLUSIONS: The UK NHS Reforms were always
going to be challenging due to their scale and complexity. However there has been
a clear lack of direction at various levels leading to uncertainty and fears for the
short and medium term future.
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OBJECTIVES: Early development of HTA in Italy has been mainly hospital-based
(HB HTA). HB HTA can support administrative procedures increasing transparency
and promoting the bottom-up awareness around HTA principles. Whether HTA
has an impact on actual hospital expenditure and consumption of health technol-
ogies, particularly medical devices (MDs), has not been investigated. This research
aimed at exploring potential HB HTA’s impact on purchased MDs, once assessed its
diffusion in Italy. METHODS: We run a survey, based on a semi structured on line
questionnaire, on a sample of Italian Healthcare trusts, asking for 2008-2009 data
about consumption and unitary costs of a class of MDs (e.g. coronary stents) and
HTA activities. HB HTA’s activities have been surveyed in terms of diffusion and
structural/organizational characteristics. We assessed in a multivariate analysis
whether an association exists between the implementation of HTA activities and
MDs diffusion at the local level. RESULTS: Given 46 respondents, located in 15
Italian Regions, 22 (48%) have a commission for MDs. Commissions meet almost
monthly and encompass on average 10 members (SD5.4). On average there are 2
pharmacists (SD1.13); 3 medical doctors (SD2.91) and 1 clinical engineer
(SD2.9). About 60% of the Commissions produce evaluation forms and repertory,
whereas about 40% produce hospital guidelines and other documents to support
procurement activities. A preliminary analysis of HB HTA’s characteristics shows
that the perception on the importance of HTA in a hospital may depend on the
presence/absence of the organizational structure (such as defined HTA Commis-
sion) and a correlation exists between expenditures/volumes of coronary stents
and level of importance of “economic” aspects in HTA. CONCLUSIONS:We suggest
HTA could potentially impact on health technologies’ uptake and expenditure
when realized within the hospital setting, stimulating collaboration between dif-
ferent units and actors, thus providing local health care managers with a useful
tool for budget control and planning.
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OBJECTIVES: Cataract surgery is commonly performed in developed countries.
Artificial lens implantation is considered to be one of the most cost-effective med-
ical interventions. The aim of this analysis was to describe the organization of
cataract surgery in Poland and compare access and quality of care with other
countries. METHODS: Access to cataract surgeries was assessed on the base of
statistical reports issued by National Health Fund (NHF) regarding number and
structure of cataract surgeries and waiting times. Epidemiological data was used to
estimate number of patients qualifying for treatment. Data on reimbursement was
obtained from Ministry of Health and NHF. To supplement publicly available data,
a number of clinical experts were consulted. RESULTS: Each year 170k cataract
surgeries are reimbursed in Poland. 300k patients are currently in a queue for
surgery. The mean waiting time is geographically dependent and varies from 8 up
to 22 months (stable cases). There is a high disproportion among voivodeships in
funding of cataract surgeries. The Cataract Surgery Rate (CSR) in 2011 was 4.4k
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